Nebivololo E Idroclorotiazide Eg (Hydrochlorothiazide, Nebivolol)

Nebivolol, the active ingredient in Nebivolol/Hydrochlorothiazide, is a beta‑blocker presented as a tablet for oral use. It works together with hydrochlorothiazide to lower blood pressure in adult patients diagnosed with hypertension and is commonly prescribed.

GNH USA supplies Nebivolol/Hydrochlorothiazide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antihypertensive medicines. The product complies with EU regulatory standards and is manufactured under GMP conditions, ensuring consistent potency and safety for patients across diverse markets.

Nebivolol/Hydrochlorothiazide is an antihypertensive combination that targets blood pressure regulation.

- Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Essential hypertension: improves overall blood pressure control when monotherapy is insufficient. - High blood pressure: assists in achieving target blood pressure levels as part of a therapeutic regimen.

Adverse reactions may occur with nebivolol/hydrochlorothiazide therapy.

Common Side Effects: - Dizziness: transient light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness or reduced energy. - Increased urination: due to diuretic action. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant hyponatremia or hypokalemia. - Acute kidney injury: sudden reduction in renal function. - Pancreatitis: inflammation of the pancreas. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, consider the following precautions.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: evaluate kidney function, especially in patients with pre‑existing impairment. - Electrolyte surveillance: check serum potassium and sodium periodically. - Caution in asthma/COPD: beta‑blockade may exacerbate bronchospasm. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at below 25°C: keep in the original pack, protect from moisture.

Nebivolol/hydrochlorothiazide may interact with other medicines.

Major Interactions (Avoid): - Other antihypertensives: additive blood‑pressure lowering effect may cause hypotension. - Potassium‑sparing diuretics: risk of hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - NSAIDs: may reduce diuretic efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Digoxin: increased risk of digoxin toxicity. - Antidiabetic agents: may enhance hypoglycaemic effect, requiring dose adjustment.